Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PRNP | P04156 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24257971 | 0.94 | SMN1; SMN2 (0.48) | SMN1; SMN2AKR1C3AKR1C2LMNAPRNP | |
| SCHEMBL30575774 | 0.94 | SMN1; SMN2 (0.48) | SMN1; SMN2AKR1C3AKR1C2LMNAPRNP | |
| SCHEMBL22149208 | 0.90 | SMN1; SMN2 (0.44) | SMN1; SMN2AKR1C3AKR1C2LMNAPRNP | |
| SCHEMBL14915840 | 0.87 | SMN1; SMN2 (0.54) | SMN1; SMN2AKR1C3AKR1C2LMNAKDM4E | |
| SCHEMBL14915520 | 0.84 | SMN1; SMN2 (0.51) | SMN1; SMN2AKR1C3AKR1C2LMNAKDM4E | |
| SCHEMBL14914576 | 0.80 | TSHR (0.47) | SMN1; SMN2LMNAKDM4ETDP1ALDH1A1 | |
| SCHEMBL2554045 | 0.79 | SMN1; SMN2 (0.53) | SMN1; SMN2AKR1C3AKR1C2LMNAKDM4E | |
| SCHEMBL8325804 | 0.78 | MMP8 (0.53) | LMNAKDM4EPOLBNPC1TDP1 | |
| SCHEMBL1044605 | 0.77 | ALDH1A1 (0.45) | LMNAKDM4EPOLBNPC1RAB9A | |
| SCHEMBL4262705 | 0.76 | MAPT (0.48) | SMN1; SMN2AKR1C3AKR1C2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308610-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2019-06-04 | — | — | US | disclosed |
| US-20180099936-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-04-12 | — | — | US | disclosed |
| US-9856220-B2 | Inhibitor compounds of phosphodiesterase type 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-01-02 | — | — | US | disclosed |
| EP-2780324-B1 | HETEROCYCLIC CARBOXAMIDES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2017-05-17 | — | — | EP | disclosed |
| US-20160318871-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. | 2016-11-03 | — | — | US | disclosed |
| EP-2780324-A1 | HETEROCYCLIC CARBOXAMIDES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | Abbvie Deutschland GmbH & Co. KG (DE) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013068489-A1 | HETEROCYCLIC CARBOXAMIDES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | ABBOTT GMBH & CO. KG (DE) | 2013-05-16 | — | — | WO | disclosed |
| US-20130116229-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318871-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE3A, PDE5A, PDE3B | SMN1; SMN2 1710/4885AKR1C3 107/4885AKR1C2 362/4885 |
| US-10308610-B2 | Inhibitor compounds of phosphodiesterase type 10A | PDE3A, PDE5A, PDE3B | SMN1; SMN2 1928/4885AKR1C3 76/4885AKR1C2 251/4885 |
| US-20130116229-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE7A, PDE5A, PDE2A | SMN1; SMN2 941/4885AKR1C3 2182/4885AKR1C2 1324/4885 |
| US-20180099936-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE3A, PDE5A, PDE3B | SMN1; SMN2 1689/4885AKR1C3 109/4885AKR1C2 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.